However, current treatments and clinical trials targeting these pathways, such as using inhibitors of acetylcholinesterase [15], and γ secretase [16–19] or immunotherapy targeting to Aβ and Tau [18], have not been proved to be able to stop or slow down the disease process of AD. The gene discussed is MAPT; the disease is Alzheimer disease.